- Home
- LPTX vs TLPH Comparison
LPTX vs TLPH Comparison
Compare LPTX & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- TLPH
- Stock Information
- Founded
- LPTX 2011
- TLPH 2005
- Country
- LPTX United States
- TLPH United States
- Employees
- LPTX N/A
- TLPH N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- TLPH Health Care
- Exchange
- LPTX Nasdaq
- TLPH Nasdaq
- Market Cap
- LPTX 11.1M
- TLPH 11.1M
- IPO Year
- LPTX N/A
- TLPH 2011
- Fundamental
- Price
- LPTX $0.29
- TLPH $0.54
- Analyst Decision
- LPTX Hold
- TLPH Strong Buy
- Analyst Count
- LPTX 1
- TLPH 1
- Target Price
- LPTX N/A
- TLPH $6.00
- AVG Volume (30 Days)
- LPTX 2.0M
- TLPH 3.4M
- Earning Date
- LPTX 08-14-2025
- TLPH 08-14-2025
- Dividend Yield
- LPTX N/A
- TLPH N/A
- EPS Growth
- LPTX N/A
- TLPH N/A
- EPS
- LPTX N/A
- TLPH N/A
- Revenue
- LPTX N/A
- TLPH $27,000.00
- Revenue This Year
- LPTX N/A
- TLPH N/A
- Revenue Next Year
- LPTX N/A
- TLPH $14,533.26
- P/E Ratio
- LPTX N/A
- TLPH N/A
- Revenue Growth
- LPTX N/A
- TLPH N/A
- 52 Week Low
- LPTX $0.22
- TLPH $0.38
- 52 Week High
- LPTX $4.79
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- LPTX 46.11
- TLPH 67.39
- Support Level
- LPTX $0.28
- TLPH $0.40
- Resistance Level
- LPTX $0.31
- TLPH $0.57
- Average True Range (ATR)
- LPTX 0.04
- TLPH 0.07
- MACD
- LPTX 0.00
- TLPH 0.01
- Stochastic Oscillator
- LPTX 39.39
- TLPH 55.38
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.